Cargando…
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial
Haemophilia treatment guidelines advocate early home-based treatment of acute bleeds. In the ADEPT2 trial, data were collected on the home treatment of bleeds with recombinant activated factor VII (rFVIIa) in haemophilia patients with inhibitors and self-reported bleeding-related symptoms. A total o...
Autores principales: | Lentz, Steven R., Rangarajan, Savita, Karim, Faraizah A., Andersen, Philip D., Arkhammar, Per, Rosu, Gabriela, Mahlangu, Johnny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407628/ https://www.ncbi.nlm.nih.gov/pubmed/27427786 http://dx.doi.org/10.1097/MBC.0000000000000584 |
Ejemplares similares
-
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A
por: Pasi, K John, et al.
Publicado: (2021) -
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
por: Mahlangu, Johnny N.
Publicado: (2021) -
Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022) -
Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population
por: Zahari, Maimiza, et al.
Publicado: (2018) -
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011)